Shandong Weigao Blood Purification Products Co., Ltd.

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

22093

603014

Shandong Weigao Blood Purification Products Co., Ltd. announced the implementation of the 2025 semi-annual equity distribution, planning to distribute a cash dividend of RMB 0.15756 per share based on a total share capital of 417,754,066 shares, totaling a cash dividend distribution of RMB 65,821,330.64. The equity registration date is October 23, 2025, and the ex-dividend date and cash dividend payment date is October 24. The announcement specifies the tax deduction situation for different types of shareholders

Zhitong

Weigao Blood Purification

Weigao Blood Purification will implement the distribution of equity for the first half of 2025, distributing over 65.82 million yuan in cash

Shandong Weigao Blood Purification Products Co., Ltd. announced the 2025 restricted stock incentive plan, granting 6.36 million restricted shares to 120 incentive recipients, with a grant price of 19.77 yuan per share. The plan has a maximum validity period of 48 months, with a lock-up period starting from the registration date, and the first release of the lock-up period will be no less than 12 months. The registration is expected to be completed on September 29, raising 125.7 million yuan for liquidity support, which is expected to stimulate employee motivation and enhance long-term performance

Weigao Blood Purification 2025 6.36 million restricted stock incentive plan grant results announced

The Shanghai Stock Exchange Listing Committee announced that Shandong Weigao Blood Purification Products Co., Ltd. has been approved for its initial public offering

Shanghai Stock Exchange Listing Committee: Weigao Blood Purification's IPO approved

Shandong Weigao Blood Purification Products Co., Ltd. went public on the Shanghai Stock Exchange on February 26, aiming to raise 1.351 billion yuan, with Huatai United Securities as the sponsor. The company focuses on the fields of hemodialysis and peritoneal dialysis, with a rich product line that meets the needs of end-stage renal disease patients. From 2021 to the first half of 2024, the company's operating income has increased year by year, and net profit has also shown an upward trend

Weigao Blood Purification has passed the IPO review at the Shanghai Stock Exchange, focusing on the two major sectors of hemodialysis and peritoneal dialysis

Shandong Weigao Blood Purification Products Co., Ltd.(N22093.HK)

Weigao Blood Purification will implement the distribution of equity for the first half of 2025, distributing over 65.82 million yuan in cash

Weigao Blood Purification 2025 6.36 million restricted stock incentive plan grant results announced

Shanghai Stock Exchange Listing Committee: Weigao Blood Purification's IPO approved

Weigao Blood Purification has passed the IPO review at the Shanghai Stock Exchange, focusing on the two major sectors of hemodialysis and peritoneal dialysis